Otsuka Holdings Co., Ltd. (OTSKF)
| Market Cap | 36.94B |
| Revenue (ttm) | 15.83B |
| Net Income (ttm) | 2.37B |
| Shares Out | n/a |
| EPS (ttm) | 4.48 |
| PE Ratio | 15.60 |
| Forward PE | n/a |
| Dividend | 0.89 (1.37%) |
| Ex-Dividend Date | Jun 29, 2026 |
| Volume | 100 |
| Average Volume | 529 |
| Open | 64.57 |
| Previous Close | 64.57 |
| Day's Range | 64.57 - 64.57 |
| 52-Week Range | 44.40 - 72.22 |
| Beta | -0.08 |
| RSI | 53.50 |
| Earnings Date | Apr 28, 2026 |
About Otsuka Holdings
Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. It develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, autoimmune space digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment and tools, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement... [Read more]
Financial Performance
In 2025, Otsuka Holdings's revenue was 2.47 trillion, an increase of 5.97% compared to the previous year's 2.33 trillion. Earnings were 363.15 billion, an increase of 5.84%.
Financial numbers in JPYNews
US FDA approves Otsuka's kidney disease drug
The U.S. Food and Drug Administration has approved Otsuka's injectable drug to treat patients with a potentially life-threatening kidney disease, the health regulator's website showed on Tuesday.
Shares of Asian drugmakers drop after Trump threatens tariffs
Shares of Asian drugmakers mostly fell on Friday after U.S. President Donald Trump threatened 100% tariffs on imports of branded pharmaceuticals from October 1, unless their producers had already brok...